In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Novartis Venture Funds leads Visiogen's $40mm Series E round
30 Apr 2009
Novartis Venture Funds has led the $40mm Series E financing for Visiogen (presbyopia- and cataract-correcting devices) and contributed a new board member. Technology Partners, another first-time investor, also contributed significantly and was joined by existing backers Three Arch Partners, New Leaf Venture Partners, Prospect Venture Partners, CMEA Ventures, and Foundation Medical Partners. The company will use the money to fund global commercialization of its accommodating intra-ocular lens Synchrony, which was recently launched in Europe and could be approved in the US next year. Including this round, Visiogen has raised over $80mm since it was founded in 2001.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?